An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2
Proceedings of the National Academy of Sciences · 2026
DOI: 10.1073/pnas.2519857123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Yuan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, Hubei 430070, China. Hauptthemen laut MEDLINE: Immunity, Mucosal, SARS-CoV-2, Influenza A virus, Vaccines, Virus-Like Particle. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOE | Fundamental Research Funds for the Central Universities (Fundamental Research Fund for the Central Universities), MOST | NSFC | NSAF Joint Fund.
Abstract (Originalsprache)
Integrating complementary vaccine modalities is essential for combating emerging pathogens. Although the recent mRNA-VLP hybrids enable spontaneous virus-like particles (VLPs) self-assembly, thereby enhancing immunogenicity, they fail to elicit robust pulmonary mucosal immunity against respiratory pathogens. Here, we developed Ad5-Envp-VLP, a chimeric adenoviral platform enabling spontaneous in vivo assembly of envelope protein-displaying VLPs using advanced technology that recruits ESCRT (endosomal sorting complex required for transport) via the EABR (ESCRT and ALIX-binding region). Compared with the intramuscular route, intranasal administration of a single-dose Ad5-HA-VLP confers long-lasting protection against both homologous and heterologous influenza A strains. Integrated single-cell RNA sequencing and flow cytometry analyses reveal that intranasal delivery of Ad5-HA-VLP recruits and functionally reprograms lung innate immune cells, promoting antigen presentation and driving robust mucosal secretory IgA (sIgA) secretion and cytotoxic T lymphocyte responses. Similarly, intranasal delivery of Ad5-S-VLP elicits potent cross-neutralizing antibody titers against SARS-CoV-2 variants. Importantly, intranasal immunization with Ad5-S-HA-VLP (coexpressing S- and HA-VLPs) generates dual influenza and SARS-CoV-2 neutralizing antibodies, alongside pulmonary antigen-specific sIgA, confirming Ad5-Envp-VLP as a promising “single-dose multiplexed mucosal vaccine” against respiratory pathogens. Further extended applications show that Ad5-RVDG-VLP also induces broad protective immunity in mouse, dog, and cat models, verifying its feasibility as an efficient rabies vaccine. Collectively, the Ad5-Envp-VLP platform represents a universal and versatile mucosal vaccine strategy, leveraging pulmonary delivery of vectors that encode in vivo-assembling VLPs to concurrently elicit robust mucosal and systemic immunity against a wide spectrum of pathogens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, Hubei 430070, China.
- Frontiers Science Center for Animal Breeding and Sustainable Production, Huazhong Agricultural University, Wuhan, Hubei 430070, China.
- Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Hubei 430070, China.
- Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
- Hubei Hongshan Laboratory, Wuhan, Hubei 430070, China.
- Hubei Jiangxia Laboratory, Wuhan, Hubei 430070, China.
ORCID-Profile: Yuan Zhang, Ming Zhou, Zhen F Fu, Ling Zhao
Förderung
- MOE | Fundamental Research Funds for the Central Universities (Fundamental Research Fund for the Central Universities)
- MOST | NSFC | NSAF Joint Fund
Zitieren
APA
Zhang, Y., Wang, C., Zheng, Y., Chen, F., Feng, Y., Fang, L., Wang, Z., Zhou, M., Fu, Z. F., & Zhao, L. (2026). An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2519857123
Vancouver
Zhang Y, Wang C, Zheng Y, Chen F, Feng Y, Fang L, et al. An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2519857123
BibTeX
@article{Zhang2026,
author = {Zhang, Yuan and Wang, Caiqian and Zheng, Yanhong and Chen, Feiyu and Feng, Yaya and Fang, Lingying and Wang, Zongmei and Zhou, Ming and Fu, Zhen F and Zhao, Ling},
title = {An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
doi = {10.1073/pnas.2519857123}
}
EUVIMED